Acta Med. 2017, 60: 71-75
https://doi.org/10.14712/18059694.2017.96
Inflammatory Biomarkers and Liver Histopathology in Non-Uremic and Uremic Chronic Hepatitis C Patients
References
1. Hepatology 2001; 34: 809–816.
< AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. https://doi.org/10.1053/jhep.2001.27831>
2. Liver Int 2009; 29(Suppl 19): 74–81.
< D. The global burden of hepatitis C. https://doi.org/10.1111/j.1478-3231.2008.01934.x>
3. Arch Intern Med 2011; 171: 242–8.
< IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982–2006. https://doi.org/10.1001/archinternmed.2010.511>
4. Liver Int 2012; 32(Suppl 1): 2–8.
< V, Craxi A. 2011 Europian Association of THA Study of Liver hepatitis C virus clinical practice guidelines. https://doi.org/10.1111/j.1478-3231.2011.02703.x>
5. World J Hepatol 2015; 7: 548–58.
< S, Boletis JN, Sakellariou S, Delladetsima IK. Hepatitis C in hemodialysis patients. https://doi.org/10.4254/wjh.v7.i3.548>
<PubMed>
6. Semin Liver Dis 2006; 26: 318–27.
< CP, Manns MP. Approaches to liver biopsy techniques – revisited. https://doi.org/10.1055/s-2006-951599>
7. J Viral Hepat 2012; 19(Suppl 1): 18–32.
< G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? https://doi.org/10.1111/j.1365-2893.2011.01518.x>
8. Rev Med Virol 2005; 15: 235–68.
< C, Cerny A. Hepatitis C virus and the immune system: a concise review. https://doi.org/10.1002/rmv.466>
9. J Hepatol 2000; 32: 121–5.
< MP, Golden-mason L, Nolan N, et al. Expansion of peripheral blood CD5+ B cells is associated with mild disease in chronic C virus infection. https://doi.org/10.1016/S0168-8278(00)80198-1>
10. Clin Immunol 2008; 128: 133–47.
< S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. https://doi.org/10.1016/j.clim.2008.03.525>
<PubMed>
11. Expert Rev Cardiovasc Ther 2013; 11: 55–9.
< T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. https://doi.org/10.1586/erc.12.159>
12. Acta Clin Belg 2016; 71: 221–6.
< E, Mirili C, Isikyakar T, et al. The association of neutrophil/ lymphocyte ratio and platelet/lymphocyte ratio with clinical outcomes in geriatric patients with stage 3–5 chronic kidney disease. https://doi.org/10.1080/17843286.2016.1159797>
13. Platelets 2015; 26: 638–44.
< B, Akin F, Celik O, et al. Platelet to lymphocyte ratio as a prognostic marker in primary percutaneous coronary intervention. https://doi.org/10.3109/09537104.2014.968117>
14. Dan Med Bull 2006; 53: 172–209.
JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer.
15. Ann Hepatol 2012; 11: 855–61.
TG, Staub GJ, Lazzarotto C, et al. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C.
16. World J Gastroenterol 2005; 11: 476–81.
< Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. https://doi.org/10.3748/wjg.v11.i4.476>
<PubMed>
17. Hepatology 2007; 46: 307–14.
< LL, Schiavon JL, Filho RJ, et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. https://doi.org/10.1002/hep.21681>
18. J Viral Hepat 2008; 15: 666–74.
< LL, Narciso-Schiavon JL, Carvalho Filho RJ, et al. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. https://doi.org/10.1111/j.1365-2893.2008.00992.x>
19. J Hepatol 2009; 50: 370–6.
< ML, Papen S, Pauels K, et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. https://doi.org/10.1016/j.jhep.2008.09.016>
20. Scand J Gastroenterol 2010; 45: 615–22.
< LL, Carvalho-Filho RJ, Narciso-Schiavon JL, et al. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. https://doi.org/10.3109/00365521003637203>
21. Hepatogastroenterology 2007; 54: 493–8.
S, Hirayama C, Horie Y, et al. Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome.
22. Hepatogastroenterology 2003; 50: 2121–6.
A, Alende MR, Gamallo R, et al. Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease.
23. J Viral Hepat 2004; 11: 251–6.
< K, Uhanova J, Gong Y, Kaita K, Doucette K, Pettigrew N, et al. Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. https://doi.org/10.1111/j.1365-2893.2004.00507.x>
24. Clin Transplant 2007; 21: 391–7.
< H, Cohen M, Pappo O, et al. Serum globulin levels in predicting the extent of hepatic fibrosis in patients with recurrent post-transplant hepatitis C infection. https://doi.org/10.1111/j.1399-0012.2007.00657.x>
25. Dis Markers 2014; 2014: 462958.
< MT, Hu TH, Lu SN, et al. Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C. https://doi.org/10.1155/2014/462958>
<PubMed>